Genzyme may delay production plans for Myozyme

NEW YORK Genzyme said Wednesday that its plans to boost production of the drug Myozyme face possible delays, causing its shares to fall 4.3 percent despite increases in profits.

Myozyme, known generically as alglucosidase alfa, is used to treat Pompe disease, a genetic illness that impairs muscles.

Genzyme launched Myozyme in 2006, and it has since been approved in 36 countries.